Trial Profile

A Phase 3 trial of oral MRX-1 to treat complicated skin and skin structure infections (cSSSI) in China

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Jun 2021 According to a MicuRx Pharmaceuticals media release, the China National Medical Products Administration (NMPA) has approved new drug application for contezolid as the treatment of complicated skin and soft tissue infection, based on data from this trial.
19 Sep 2019 Primary endpoint (Noninferiority compared to linezolid for the Clinical cure rate at the test-of-cure visit (TOC visit, 7-14 days after the last dose of study drug)) has been met, according to the MicuRx Pharmaceuticals media release.
19 Sep 2019 According to a MicuRx media release, the company plan to file a New Drug Application with the National Medical Products Administration (NMPA) of China in the 4th quarter of 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com